Apimeds Pharmaceuticals US (APUS) vs BioLineRx (BLRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BioLineRx (BLRX) has outperformed Apimeds Pharmaceuticals US (APUS) over the past year, losing 50.3% versus a loss of 58.8%. BioLineRx is the larger company by market cap ($11.0 million vs $10.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APUS | BLRX |
|---|---|---|
| Share price | $7.05 | $2.21 |
| Market cap | $10.64M | $10.98M |
| 1-day change | -1.12% | -3.80% |
| YTD return | -57.01% | -20.40% |
| 1-year return | -58.77% | -50.34% |
| 5-year return | — | -98.20% |
| EPS (TTM) | $-35.63 | $0.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $59.70 | $4.50 |
| 52-week low | $1.51 | $2.15 |
| Distance from 52-week high | -88.19% | -51.00% |
| Average volume | 3.36M | 16.15K |
| Shares outstanding | 1.51M | 4.98M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
APUS vs BLRX FAQ
Which is bigger, Apimeds Pharmaceuticals US or BioLineRx?
BioLineRx (BLRX) is larger, with a market capitalization of $10.98M compared with $10.64M for Apimeds Pharmaceuticals US (APUS).
Which stock has performed better over the past year, APUS or BLRX?
BLRX returned -50.34% over the past 12 months, compared with -58.77% for APUS (price return, excluding dividends). Past performance does not predict future results.
Are Apimeds Pharmaceuticals US and BioLineRx in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.